Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 30193264.
- Also identified by DOI 10.1001/jama.2018.7316 and PMC identifier 6142992.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study estimates mean 2017 total and out-of-pocket costs for infliximab and its biosimilar infliximab-dyyb under Medicare Part D.
Medical subject headings
- Antirheumatic Agents
- Biosimilar Pharmaceuticals
- Cost Sharing
- Financing, Personal
- Infliximab